<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01894334</url>
  </required_header>
  <id_info>
    <org_study_id>2011-2006-03</org_study_id>
    <nct_id>NCT01894334</nct_id>
  </id_info>
  <brief_title>Mechanism and Early Intervention Research on ALI During Emergence Surgery of Acute Stanford A Aortic Dissection</brief_title>
  <official_title>Mechanism and Early Intervention Research on Acute Lung Injury During Emergence Surgery of Acute Stanford A Aortic Dissection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Beijing Anzhen Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Beijing Anzhen Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The morbidity rate of Stanford A type Acute Aortic Dissection（AAD） has been increasing, about&#xD;
      5-10/100,000* per year. Emergency surgery has been the main treatment for Acute Aortic&#xD;
      Dissection, however perioperative mortality rate can be as high as 15~30%. Acute lung injury&#xD;
      (ALI) is one of the main complications that happen during the perioperative period, which by&#xD;
      itself covers 30%-50% of the overall mortality rate. Both domestic and foreign countries lack&#xD;
      researches on risk factors, pathogenesis, disease progression and outcome of ALI, which&#xD;
      happen during the perioperative period of Acute Aortic Dissection patients.&#xD;
&#xD;
      This topic study follow projects in the preoperative of Acute Aortic Dissection'surgery&#xD;
&#xD;
        1. hemodynamic changes (aortic dissection resulting in acute aortic regurgitation, cardiac&#xD;
           tamponade and proximal high blood pressure)&#xD;
&#xD;
        2. ischemia - reperfusion injury of aortic dissection distal organ&#xD;
&#xD;
        3. Aortic intima-media exposure cause coagulation / fibrinolytic system function disorder&#xD;
&#xD;
        4. systemic inflammatory response syndrome; use relevant clinical radiographic parameters,&#xD;
           indicators of respiratory mechanics (oxygenation index and lung injury index) and&#xD;
           biochemical indicators.&#xD;
&#xD;
      To discuss risk factors and possible mechanisms of ADD patients with pre-operative ALI and&#xD;
      observe their influences on the progress and prognosis of AAD, to explore early intervention&#xD;
      in the preoperative for possible risk factors and mechanisms and to evaluate their influences&#xD;
      on the prognosis, to achieve the purpose of reducing AAD perioperative mortality of ALI and&#xD;
      medical expenses.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">January 2015</completion_date>
  <primary_completion_date type="Anticipated">January 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>perioperative outcome and improve of ALI</measure>
    <time_frame>Period from 48 hours before surgery to 12 hours after ICU</time_frame>
    <description>indicators&#xD;
chest imaging (preoperative, 12 hours after ICU);&#xD;
arterial blood gases and alveolar-arterial oxygen difference (before surgery, and immediately after induction of anesthesia, before surgery ends and 12 hours after ICU);&#xD;
respiratory mechanics (immediately after induction of anesthesia, before the end of surgery and 12 hours after ICU); including peak airway pressure, plateau pressure, dynamic and static compliance and so on.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>systemic inflammatory response</measure>
    <time_frame>Period from 48 hours before surgery to 12 hours after ICU</time_frame>
    <description>Indicators&#xD;
Lung lavage (immediately after induction of anesthesia、before the end of surgery)&#xD;
determination of imflammatory cytokines (IL-6, IL-8, Tumor Necrosis Factor -α, Cluster of Differentiation 11 /Cluster of Differentiation 18 , myeloperoxidase) and surface-active substance</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">220</enrollment>
  <condition>Acute Aortic Dissection</condition>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no intervention</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tranexamic acid group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>tranexamic acid ，intravenous 30mg/kg/d，Preoperative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Edaravone group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>edaravone, iv, 1mg/kg/d,Preoperative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ulinastatin group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ulinastatin ,iv，20,000 U /kg/d，Preoperative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ulinastatin</intervention_name>
    <arm_group_label>Ulinastatin group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic acid</intervention_name>
    <arm_group_label>Tranexamic acid group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Edaravone</intervention_name>
    <arm_group_label>Edaravone group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  AAD patients within 48 hrs of onset who are prepared for aortic surgery&#xD;
&#xD;
          -  Age between 18 and 70&#xD;
&#xD;
          -  Willing to sign the informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A history of chronic respiratory disease before onset&#xD;
&#xD;
          -  A history of chronic heart failure or coronary heart disease before onset&#xD;
&#xD;
          -  A history of chronic liver or kidney dysfunction before onset&#xD;
&#xD;
          -  Severe central nervous system syndrome after admission&#xD;
&#xD;
          -  Refuse to sign the informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>WeiPing Cheng, master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chief Physician，Professor</affiliation>
  </overall_official>
  <verification_date>January 2014</verification_date>
  <study_first_submitted>June 8, 2013</study_first_submitted>
  <study_first_submitted_qc>July 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2013</study_first_posted>
  <last_update_submitted>January 23, 2014</last_update_submitted>
  <last_update_submitted_qc>January 23, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 24, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Beijing Anzhen Hospital</investigator_affiliation>
    <investigator_full_name>WeiPing Cheng</investigator_full_name>
    <investigator_title>Professor；Chief Physician</investigator_title>
  </responsible_party>
  <keyword>Aortic dissection</keyword>
  <keyword>acute lung injury</keyword>
  <keyword>injury mechanism</keyword>
  <keyword>early intervention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Aneurysm, Dissecting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Edaravone</mesh_term>
    <mesh_term>Tranexamic Acid</mesh_term>
    <mesh_term>Urinastatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

